Cambium Bio Ltd CMB
Trading Information
- Previous Close Price
- A$0.55
- Day Range
- A$0.54–0.54
- 52-Week Range
- A$0.34–0.60
- Bid/Ask
- A$0.45 / A$0.54
- Shares Outstanding
- 29.43M
- Market Cap
- A$15.89M
- Volume/Avg
- 64 / 9,352
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. The company operates in the USA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.cambium.bio
Valuation
|
Metric
|
CMB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CMB
Financial Strength
|
Metric
|
CMB
|
|---|---|
Quick Ratio | 0.93 |
Current Ratio | 0.95 |
Interest Coverage | −298.12 |
Quick Ratio
CMB
Profitability
|
Metric
|
CMB
|
|---|---|
Return on Assets (Normalized) | −106.11% |
Return on Equity (Normalized) | −164.48% |
Return on Invested Capital (Normalized) | −142.50% |
Return on Assets
CMB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zX>S!^ | LOCK|<$g#h | $129B | |||
| Moderna Inc
MRNA
| LOCK|xHGpzK> | LOCK|>@# | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|k<<#H@ | LOCK|VC#X | $79B | |||
| argenx SE ADR
ARGX
| LOCK|d%w@@n | LOCK|@t | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|vK#dYYH | LOCK|kd | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>?@$vpb | LOCK|%mMDl | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|yY@gH$> | LOCK|fdxqt | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|?Q&@SQ | LOCK|^vp | $24B | |||
| Incyte Corp
INCY
| LOCK|KJ?&JFR | LOCK|<sl | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%Fjq$k | LOCK|#$ | $14B |
United States